Chronic Lymphocytic Leukemia: Pirtobrutinib vs. Ibrutinib

We are comparing the effectiveness of pirtobrutinib to ibrutinib in patients with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma. This study also focuses on those who are newly diagnosed and have a specific genetic change.

What diseases are being studied?

Health conditions and diseases that the clinical trial is designed to study and treat.

Who can participate in the clinical trial?

These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..

What active substances are being studied?

Active substances that are officially approved for use in the European Union and considered safe by EMA. These substances are already on the market and may be tested for new conditions or populations.

Ibrutinib
Ibrutinib is a substance that targets immune cell signaling to treat certain blood cancers, such as chronic lymphocytic leukemia and mantle cell lymphoma.
Pirtobrutinib
Pirtobrutinib is a substance that blocks a B-cell signaling protein to treat certain blood cancers like chronic lymphocytic leukemia and mantle cell lymphoma.

Where is the clinical trial being conducted?

Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.

Loading map...
Ordensklinikum Linz GmbH
Interne I: Medizinische Onkologie und Hämatologie
Linz, Austria
Hanusch Krankenhaus Der Wiener Gebietskrankenkasse
III. Medizinische Abteilung
Vienna, Austria
UZ Leuven
Hematology
Heverlee, Belgium

Sponsor: Loxo Oncology Inc.
Last updated: Nov 26, 2025

Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.